mardi 14 janvier 2020

Onco Actu du 14 janvier 2020


1. BIOLOGIE



Long-term skin irritation linked to increased risk of tumour growth [Imperial College London]











What Does Cancer Metastasis Have to Do with Wound Healing? More than You Might Think [Memorial Sloan Kettering Cancer Center]











1.1 BIOLOGIE - GÉNOME



Unique Toronto-based clinical trial reveals new subtypes of advanced pancreatic cancer [Ontario Institute for Cancer Research]











1.4 BIOLOGIE - TECHNOS, MODÈLES



A marriage of microscopy and machine learning [Broad Institute]











4.12 BIOPSIES LIQUIDES



Guardant Health Announces Collaboration With Amgen to Develop a Global Liquid Biopsy Companion Diagnostic for AMG 510 KRAS G12C Inhibitor [Guardant Health]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Genomics England and Illumina partner to deliver whole genome sequencing for England’s NHS Genomic Medicine Service [Genomics England]











4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



JPM20: Illumina Launches Super Resolution Instruments [Omics! Omics!]











Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics [Illumina]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Investigational drugs block bone loss in mice receiving chemotherapy [WUSTL]











Queen Mary research team identifies new route for tackling drug resistance in skin cancer cells [Queen Mary University of London]











5.10 TRAITEMENTS - ESSAIS



Bureaucracy is hampering the success of clinical research [BMJ]










FDA and NIH let clinical trial sponsors keep results secret and break the law [Science]










5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Incyte pays $750M upfront for rights to MorphoSys cancer drug [Fierce Biotech]











Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug [Xconomy]











Incyte turns to German Morphosys to refresh cancer pipeline [Biopharma Dive]










With sparse R&D prospects, Incyte bets $900M on MorphoSys' CAR-T rival tafasitamab [EndPoints]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Eli Lilly ditches NextCure pact [Fierce Biotech]











Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC [Lilly]











5.2 PHARMA



AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer [Fierce Pharma]











5.2.1 PHARMA - PARTENARIATS



Roche and Illumina partner to broaden patient access to genomic testing [Roche]











5.2.6 PHARMA - BIOTECH



Big Pharma partner Schrödinger wants a $100M IPO [Fierce Biotech]











RA Capital, Canaan help infuse $50M into Alta-incubated biotech battling acquired resistance to TKIs [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



The F.D.A. Is in Trouble. Here’s How to Fix It. [NY Times]










6. LUTTE CONTRE LES CANCERS



The global challenge of cancer [Nature Cancer]











A roadmap for the next decade in cancer research [Nature Cancer]










Shaping the future of cancer research at NCI [Nature Cancer]











6.1 OBSERVATION



Contrary to what we are frequently told, we are not “losing the war on cancer” (2020 edition) [Science-Based Medicine]











6.6 PUBLICATIONS



Eight publishers to volunteer pricing info in pilot study [Science]











6.7 DMP, BIG DATA & APPLIS



Axes of a revolution: challenges and promises of big data in healthcare [Nature Medicine]











Barriers to Working With National Health Service England’s Open Data [Journal of Medical Internet Research]










6.7.3 DMP



Doctors average 16 minutes on the computer for every patient [Reuters]